ERBB2 and non-Hodgkin lymphoma: Other clinical trials incorporating TGFβRII DNR expressing cells have targeted a number of cancers including nasopharyngeal carcinoma (using antigen-specific T cells directed against EBV), metastatic melanoma (using tumor infiltrating lymphocytes TILs), EBV-positive Hodgkin disease and non-Hodgkin lymphoma using antigen-specific T cells directed against EBV), and HER2+ breast cancer (using chimeric antigen receptors directed against HER2) (see Table 2).